CURRENT ADVANCEMENTS ON THE EFFICACY OF CONVALESCENT PLASMA AS A POTENTIAL PROMISING TREATMENT FOR COVID-19

Main Article Content

S. D. NGULUBE PETER
DIGVIJAY PANDEY

Abstract

Purpose: No sooner had COVID-19 hit the world in December, 2019 in Wuhan, China, than the emergence of tremendous developments on the therapeutic interventions for the pandemic. No therapy has been proved successful up to date regardless potentiality of several intervention that are still in clinical trials. However Convalescent plasma demonstrated some sort of interest to be potential for the treatment of COVID-19 as we are still waiting for a specific therapy or vaccine. This review discusses current developments that supported the efficacy of convalescent plasma to attract its potentiality for treating COVID-19.

Methods: A systematic search with a search term “efficacy of convalescent plasma on COVID-19” was done on PubMed, Google Scholar, Science direct, Research Gate and clinicaltrials.gov database. A search was conducted based on all the literature discussing the current advancements on the use of convalescent plasma as a potential treatment for coronavirus, however only studies that discussed its efficacy were retrieved in this review.

Results: We retrieved a total of 24 articles discussing the current developments on the use of convalescent plasma as a potential treatment for COVID-19. 70% of the articles discuss its success, 20% of the articles evaluate current ongoing clinical trials for convalescent plasma while the remaining 10% present concerns on the inappropriate administration of convalescent plasma as a COVID-19 therapy.

Conclusion: Several discussed studies demonstrated much attention on the use of convalescent plasma as a potential promising therapy for COVID-19, although this has not been proven. However, other studies expressed concerns over the inappropriate administration of the therapy where COVID-19 patients ended up developing a pro- thrombotic disease.

Keywords:
Convalescent plasma, coronavirus infection, pro- thrombotic disease, pneumonia.

Article Details

How to Cite
PETER, S. D. N., & PANDEY, D. (2020). CURRENT ADVANCEMENTS ON THE EFFICACY OF CONVALESCENT PLASMA AS A POTENTIAL PROMISING TREATMENT FOR COVID-19. Asian Journal of Advances in Medical Science, 2(3), 7-12. Retrieved from https://mbimph.com/index.php/AJOAIMS/article/view/1719
Section
Systematic Reviews

References

Ilona B, László G, Marienn R, Gabriella B, Lilla H, Botond L, et al. Successful administration of convalescent plasma in critically ill COVID-19 patients in Hungary: The first two cases. Orv Hetil. 2020;161(27): 1111–21.

Li L, Li L, Zhang W, Zhang W, Hu Y, Tong X, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A Randomized Clinical Trial. JAMA - J Am Med Assoc [Internet]. 2020;324(5):460–70. Available:https://jamanetwork.com/journals/jama/fullarticle/2766943

Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. The Lancet Infectious Diseases. Lancet Publishing Group. 2020;20:398–400.

Roychoudhury A. Convalescent plasma therapy: solution to COVID-19? OPEN ACCESS [Internet]. SF Journal of Medicine and Research. 2020;1. [cited 2020 Aug 28]. Available: https://scienceforecastoa.com/

Brown BL, McCullough J. Treatment for emerging viruses: Convalescent plasma and COVID-19. Transfusion and Apheresis Science. Elsevier Ltd. 2020;59.

Mucha SR, Quraishy N. Convalescent plasma for COVID-19. Cleve Clin J Med. [Internet]; 2020[cited 2020 Sep 2]. Available:https://pubmed.ncbi.nlm.nih.gov/32759176/

Mucha SR, Quraishy N. Convalescent plasma for COVID-19. Cleve Clin J Med [Internet]. 2020 Aug 5 [cited 2020 Aug 28]; Available:https://pubmed.ncbi.nlm.nih.gov/32759176/

Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. Journal of Clinical Investigation. American Society for Clinical Investigation. 2020;130:2757–65.

Rajendran K, Narayanasamy K, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. Journal of Medical Virology. John Wiley and Sons Inc.; 2020.

Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, et al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmunity Reviews. Elsevier B.V. 2020;19.

Piechotta V, Chai KL, Valk SJ, Doree C, Monsef I, Wood EM, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd. 2020;2020.

Valk SJ, Piechotta V, Chai KL, Doree C, Monsef I, Wood EM, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Vol. 2020, Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd; 2020.

Convalescent plasma: A potential therapeutic option for COVID-19 patients Ng SL, Soon TN, Yap WH, Liew KB, Lim YC, Ming LC, Tang YQ, Goh BH, - Asian Pac J Trop Med; 2020. [Internet]. [cited 2020 Aug 28] Available:http://www.apjtm.org/preprintarticle.asp?id=291408

Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA, Klassen SA, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest [Internet]; 2020. [cited 2020 Aug 28]; Available:https://www.jci.org/articles/view/140200

Psaltopoulou T, Sergentanis TN, Pappa V, Politou M, Terpos E, Tsiodras S, et al. The emerging role of convalescent plasma in the treatment of COVID-19. HemaSphere [Internet]. 2020[cited 2020 Aug 28];4(3):e409. Available:http://www.ncbi.nlm.nih.gov/pubmed/32647807

Psaltopoulou T, Sergentanis TN, Pappa V, Politou M, Terpos E, Tsiodras S, et al. The emerging role of convalescent plasma in the treatment of COVID-19. HemaSphere [Internet]. 2020[cited 2020 Sep 2];4(3): e409. Available:http://www.ncbi.nlm.nih.gov/pubmed/32647807

Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma. JAMA - J Am Med Assoc. 2020;323(16):1582–9.

Sanfilippo F, La Rosa V, Oliveri F, Astuto M. Convalescent plasma for COVID-19: the risk of pulmonary embolism should not be underestimated! Crit Care [Internet]. 2020[cited 2020 Sep 1];24(1):531. Available:http://www.ncbi.nlm.nih.gov/pubmed/32859242

Boserup B, McKenney M, Elkbuli A. An overview of current COVID-19 clinical trials and ethical considerations editorial. Ann Med Surg [Internet]; 2020 [cited 2020 Sep 1] Available:https://linkinghub.elsevier.com/retrieve/pii/S2049080120302892

Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, et al. Treatment with convalescent plasma for critically Ill patients with severe acute respiratory syndrome coronavirus 2 infection. Chest [Internet]. 2020[cited 2020 Oct 14];158(1):e9–13. Available:https://pubmed.ncbi.nlm.nih.gov/32243945/

Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A [Internet]. 2020[cited 2020 Oct 14];117(17):9490–6. Available: https://osf.io/gahz5

Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol [Internet]. 2020 [cited 2020 Oct 14];92(10):1890–901. Available:https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.25882

Ahn JY, Sohn Y, Lee SH, Cho Y, Hyun JH, Baek YJ, et al. Use of convalescent plasma therapy in two covid-19 patients with acute respiratory distress syndrome in Korea. J Korean Med Sci [Internet]. 2020[cited 2020 Oct 14];35(14). Available:https://doi.org/10.3346/jkms.2020.35.e149

Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, et al. Treatment with convalescent plasma for COVID‐19 patients in Wuhan, China. J Med Virol [Internet]. 2020[cited 2020 Aug 28];jmv.25882. Available:https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25882

Sabando Vélez BE, Plaza Meneses C, Felix M, Vanegas E, Mata VL, Romero Castillo H, et al. A practical approach for the compassionate use of convalescent plasma in patients with severe COVID-19 in developing countries. J Infect Dev Ctries. 2020;14(7):737–41.

(No Title) [Internet]. [cited 2020 Aug 28]. Available:https://www.researchgate.net/profile/Aryadeep_Roychoudhury/publication/343280997_Convalescent_Plasma_Therapy_Solution_to_COVID-19_Published_in_SF_Journal_of_Medicine_and_Research/links/5f212c3ea6fdcc9626bc9a85/Convalescent-Plasma-Therapy-Solution-to-COVID-19-Published-in-SF-Journal-of-Medicine-and-Research.pdf

FDA Issues Emergency Use Authorization for Convalescent Plasma as Potential Promising COVID–19 Treatment, Another Achievement in Administration’s Fight Against Pandemic | FDA [Internet]. [cited 2020 Aug 28]; 2020. Available:https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment

Halstead SB, Akkina R. COVID-19 and SARS Coronavirus 2: Antibodies for the Immediate Rescue and Recovery Phase. Front Immunol. 2020 May 29;11.

Ishay Y, Kessler A, Schwarts A, Ilan Y. Antibody response to SARS‐Co‐V‐2, diagnostic and therapeutic implications. Hepatol Commun [Internet]; 2020.
Available:https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep4.1600

Vandenberghe K, Van Griensven J, Voor I, Geneeskunde T, Verbeke G, Vlieghe E, et al. Michel toungouz nevessignsky croix rouge de belgique; 2020. Available:https://doi.org/10.21203/rs.3.rs-45324/v1

A H, S I, B JJ, J A, R A, Z H, et al. Low dose radiation therapy and convalescent plasma: How a hybrid method may maximize benefits for COVID-19 patients. J Biomed Phys Eng [Internet]. 2020[cited 2020 Sep 2];10(4):8. Available:https://pubmed.ncbi.nlm.nih.gov/32802787/

Hung IFN, To KKW, Lee CK, Lee KL, Yan WW, Chan K, et al. Hyperimmune IV immunoglobulin treatment: A multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest [Internet]. 2013[cited 2020 Sep 3];144(2):464–73. Available:ttps://pubmed.ncbi.nlm.nih.gov/23450336/

Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders: Report of the therapeutics and technology assessment subcommittee of the american academy of neurology. Neurology. 2012;78(13):1009–15.

Madrid PB, Panchal RG, Warren TK, Shurtleff AC, Endsley AN, Green CE, et al. Evaluation of ebola virus inhibitors for drug repurposing. ACS Infect Dis. 2016;1(7):317–26.

Hartmann J, Klein HG. Supply and demand for plasma‐derived medicinal products – a critical re‐assessment amidst the COVID ‐19 pandemic. Transfusion [Internet]. 2020 [cited 2020 Sep 1];trf.16078. Available:https://onlinelibrary.wiley.com/doi/abs/10.1111/trf.16078

Search of: convalescent plasma | Recruiting, Not yet recruiting Studies | Covid19 - List Results - ClinicalTrials.gov [Internet]; 2020. Available:https://clinicaltrials.gov/ct2/results?cond=Covid19&term=convalescent+plasma &cntry=&state=&city=&dist=&recrs=a&recrs=b